Our Company

Katja Bührer

Chief Strategy Officer

Ms. Buhrer is a biopharmaceutical executive whose extensive background spans expertise in corporate strategy, investor relations advisory, financial reporting, and capital markets. 

She was previously Vice President Corporate Development, Investor Relations, and Chief of Staff at Kindred Biosciences, a veterinary biopharmaceutical company, where she oversaw corporate strategy, investor relations, and business development. Ms. Buhrer successfully managed various business initiatives at KindredBio, including partnerships, fundraising, and was the internal project lead for the M&A process that led to the company’s acquisition by Elanco Animal Health in August 2021. Thereafter, she became Chief Operating Officer of KindredBio, responsible for the subsidiary’s day-to-day operations through the integration.

Prior to joining KindredBio, Ms. Buhrer was Managing Director at the investor relations consultancy MBS Value Partners, where she led investor relations and financial media programs for the firm’s clients, with a healthcare industry specialization. Her experience is further informed by roles in financial reporting and banking, including as an Editor, Reporter, and Columnist at The Australian Financial Review and in Capital Markets and Trading roles at Citigroup. Ms. Buhrer earned her Bachelor Commerce/Arts from the University of New South Wales, Australia. 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue